Mirum Pharmaceuticals (MIRM) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Q1 2026 earnings due May 6, 2026: Mirum is set to report after the market closes on Wednesday, May 6 (4:30 PM ET), with analysts modeling EPS of ($0.40) and revenue of about $148.8 million.
• Recent results and analyst outlook: In the prior quarter Mirum missed EPS (reported ($0.11) vs. $0.02 expected) while revenue rose ~49.8% YoY to $148.9M; Wall Street consensus is a “Moderate Buy” with a mean price target of $121.33 and forecasts of roughly ($2) EPS for the current fiscal year and $0 next year.
• Insider selling and stock metrics: Company insiders sold 89,513 shares (~$8.38M) in the last quarter (22.87% insider ownership); the stock trades near $94, market cap ~$5.73B, with a 52‑week range of $40.00–$109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) is expected to issue its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $148.8020 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). The business had revenue of $148.93 million for the quarter, compared to analysts' expectations of $141.78 million. Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The company's revenue was up 49.8% compared to the same quarter last year. During the same period last year, the business posted $1.00 earnings per share. On average, analysts expect Mirum Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mirum Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ MIRM opened at $94.00 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals has a 52 week low of $40.00 and a 52 week high of $109.28. The firm's fifty day moving average is $94.16 and its 200 day moving average is $85.07. The company has a market cap of $5.73 billion, a price-to-earnings ratio of -195.83 and a beta of 0.51.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 7,287 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $670,258.26. Following the completion of the transaction, the chief financial officer owned 49,788 shares of the company's stock, valued at approximately $4,579,500.24. The trade was a 12.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Peter Radovich sold 16,515 shares of the business's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $1,519,049.70. Following the completion of the transaction, the chief operating officer directly owned 40,272 shares of the company's stock, valued at approximately $3,704,218.56. This trade represents a 29.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 89,513 shares of company stock worth $8,377,249. 22.87% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. CIBC Private Wealth Group LLC purchased a new position in Mirum Pharmaceuticals in the 4th quarter worth about $32,000. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $33,000. Comerica Bank increased its position in shares of Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the last quarter. Quarry LP purchased a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter valued at about $41,000. Finally, Osaic Holdings Inc. increased its position in shares of Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company's stock valued at $56,000 after purchasing an additional 351 shares during the last quarter.

Wall Street Analysts Forecast Growth

MIRM has been the topic of several analyst reports. Evercore set a $126.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, March 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Leerink Partners cut their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an "outperform" rating on the stock in a report on Thursday, February 26th. Citizens Jmp reiterated a "market outperform" rating and issued a $132.00 price target on shares of Mirum Pharmaceuticals in a report on Tuesday, April 21st. Finally, Royal Bank Of Canada cut their price target on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an "outperform" rating on the stock in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $121.33.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.